

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Nanologica's Rights Issue Registered - Conversion of BTU to Shares and warrants

Nanologica AB's (publ) rights issue of units has, except for the part covered by the underwriting commitment, now been registered with the Swedish Companies Registration Office. Last day of trading in paid subscribed units is October 30, 2024.

The rights issue has, except for the part covered by the underwriting commitment, now been registered with the Swedish Companies Registration Office and the last day for trading in paid subscribed units ("**BTU**") is October 30, 2024. The stop date at Euroclear is November 4, 2024, after which the BTUs are converted into shares and warrants of series TO 2024/2025 on November 6, 2024. The newly issued shares and warrants are expected to be available in each shareholder's custody/securities account on November 6, 2024.

As a result of the regulations for insider trading, and in accordance with the resolution on the Rights Issue, subscription and allotment of Units covered by the underwriting commitment are expected to be completed during week 46. Thereafter, the rights issue will in this final part be registered with the Swedish Companies Registration Office.

ISIN code for share in Nanologica, ticker NICA: SE0005454873

ISIN code for warrants of series TO 2024/2025, ticker NICA TO5: SE0023111836

ISIN code for BTU in Nanologica, ticker NICA BTU: SE0023111851

For further information, please contact

Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

Attachments

[Nanologica's Rights Issue Registered - Conversion of BTU to Shares and warrants](#)